Scinai Immunotherapeutics Statistics
Total Valuation
SCNI has a market cap or net worth of $3.03 million. The enterprise value is $20.78 million.
Important Dates
The next estimated earnings date is Tuesday, October 29, 2024, before market open.
Earnings Date | Oct 29, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
SCNI has 838,578 shares outstanding. The number of shares has increased by 96.30% in one year.
Shares Outstanding | 838,578 |
Shares Change (YoY) | +96.30% |
Shares Change (QoQ) | +25.87% |
Owned by Insiders (%) | 7.76% |
Owned by Institutions (%) | 2.36% |
Float | 730,725 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 6.50 |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 73.15 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19
Current Ratio | 2.19 |
Quick Ratio | 1.91 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -28.35% |
Return on Capital (ROIC) | -31.73% |
Revenue Per Employee | $9,161 |
Profits Per Employee | -$119,484 |
Employee Count | 31 |
Asset Turnover | 0.02 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.78% in the last 52 weeks. The beta is 2.48, so SCNI's price volatility has been higher than the market average.
Beta (5Y) | 2.48 |
52-Week Price Change | -62.78% |
50-Day Moving Average | 3.96 |
200-Day Moving Average | 4.64 |
Relative Strength Index (RSI) | 48.23 |
Average Volume (20 Days) | 38,063 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SCNI had revenue of $284,000 and -$3.70 million in losses. Loss per share was -$7.24.
Revenue | 284,000 |
Gross Profit | -164,000 |
Operating Income | -7.88M |
Pretax Income | -19.70M |
Net Income | -3.70M |
EBITDA | -7.00M |
EBIT | -7.88M |
Loss Per Share | -$7.24 |
Full Income Statement Balance Sheet
The company has $3.08 million in cash and $20.82 million in debt, giving a net cash position of -$17.75 million or -$21.16 per share.
Cash & Cash Equivalents | 3.08M |
Total Debt | 20.82M |
Net Cash | -17.75M |
Net Cash Per Share | -$21.16 |
Equity (Book Value) | -7.28M |
Book Value Per Share | -8.70 |
Working Capital | 1.99M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$6.67 million and capital expenditures -$262,000, giving a free cash flow of -$6.93 million.
Operating Cash Flow | -6.67M |
Capital Expenditures | -262,000 |
Free Cash Flow | -6.93M |
FCF Per Share | -$8.26 |
Full Cash Flow Statement Margins
Gross Margin | -57.75% |
Operating Margin | -2,774.65% |
Pretax Margin | -1,304.23% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |